help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roth, J. M.
Right arrow Articles by Brooks, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roth, J. M.
Right arrow Articles by Brooks, P. C.
(American Journal of Pathology. 2005;166:901-911.)
© 2005 American Society for Investigative Pathology

Recombinant {alpha}2(IV)NC1 Domain Inhibits Tumor Cell-Extracellular Matrix Interactions, Induces Cellular Senescence, and Inhibits Tumor Growth in Vivo

Jennifer M. Roth, Abebe Akalu, Anat Zelmanovich, Desiree Policarpio, Bruce Ng, Shannon MacDonald, Silvia Formenti, Leonard Liebes and Peter C. Brooks

From the Departments of Radiation Oncology and Cell Biology, New York University School of Medicine, New York, New York

Cellular interaction with the extracellular matrix is thought to be a critical event in controlling angiogenesis and tumor growth. In our previous studies, genetically distinct noncollagenous (NC) domains of type-IV collagen were shown to interact with integrin receptors expressed on the surface of endothelial cells. Moreover, these NC1 domains were shown to inhibit angiogenesis in vivo. Here, we provide evidence that a recombinant form of the {alpha}2(IV)NC1 domain of type-IV collagen could bind integrins {alpha}1ß1 and {alpha}vß3 expressed on melanoma cells and inhibit tumor cell adhesion in a ligand-specific manner. Systemic administration of recombinant {alpha}2(IV)NC1 domain potently inhibited M21 melanoma tumor growth within full thickness human skin and exhibited a dose-dependent inhibition of tumor growth in nude mice. Interestingly, {alpha}2(IV)NC1 domain enhanced cellular senescence in tumor cells in vitro and in vivo. Taken together, these results suggest that recombinant {alpha}2(IV)NC1 domain is not only a potent anti-angiogenic reagent, but it also directly impacts tumor cell behavior. Thus, {alpha}2(IV)NC1 domain represents a potent inhibitor of tumor growth by impacting both endothelial and tumor cell compartments.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
L. G. Wang, E. M. Johnson, Y. Kinoshita, J. S. Babb, M. T. Buckley, L. F. Liebes, J. Melamed, X.-M. Liu, R. Kurek, L. Ossowski, et al.
Androgen Receptor Overexpression in Prostate Cancer Linked to Pur{alpha} Loss from a Novel Repressor Complex
Cancer Res., April 15, 2008; 68(8): 2678 - 2688.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. M. Borza, D.-B. Borza, V. Pedchenko, M. A. Saleem, P. W. Mathieson, Y. Sado, H. M. Hudson, A. Pozzi, J. Saus, D. R. Abrahamson, et al.
Human Podocytes Adhere to the KRGDS Motif of the {alpha}3{alpha}4{alpha}5 Collagen IV Network
J. Am. Soc. Nephrol., April 1, 2008; 19(4): 677 - 684.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. S. Boosani, A. P. Mannam, D. Cosgrove, R. Silva, K. M. Hodivala-Dilke, V. G. Keshamouni, and A. Sudhakar
Regulation of COX-2 mediated signaling by {alpha}3 type IV noncollagenous domain in tumor angiogenesis
Blood, August 15, 2007; 110(4): 1168 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Cretu, J. M. Roth, M. Caunt, A. Akalu, D. Policarpio, S. Formenti, P. Gagne, L. Liebes, and P. C. Brooks
Disruption of Endothelial Cell Interactions with the Novel HU177 Cryptic Collagen Epitope Inhibits Angiogenesis
Clin. Cancer Res., May 15, 2007; 13(10): 3068 - 3078.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Akalu, J. M. Roth, M. Caunt, D. Policarpio, L. Liebes, and P. C. Brooks
Inhibition of Angiogenesis and Tumor Metastasis by Targeting a Matrix Immobilized Cryptic Extracellular Matrix Epitope in Laminin
Cancer Res., May 1, 2007; 67(9): 4353 - 4363.
[Abstract] [Full Text] [PDF]

Home page
 Protein Sci.Home page
S. Monaco, V. Sparano, M. Gioia, D. Sbardella, D. Di Pierro, S. Marini, and M. Coletta
Enzymatic processing of collagen IV by MMP-2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains
Protein Sci., December 1, 2006; 15(12): 2805 - 2815.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. M. Borza, A. Pozzi, D.-B. Borza, V. Pedchenko, T. Hellmark, B. G. Hudson, and R. Zent
Integrin {alpha}3beta1, a Novel Receptor for {alpha}3(IV) Noncollagenous Domain and a Trans-dominant Inhibitor for Integrin {alpha}vbeta3
J. Biol. Chem., July 28, 2006; 281(30): 20932 - 20939.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Khoshnoodi, K. Sigmundsson, J.-P. Cartailler, O. Bondar, M. Sundaramoorthy, and B. G. Hudson
Mechanism of Chain Selection in the Assembly of Collagen IV: A PROMINENT ROLE FOR THE {alpha}2 CHAIN
J. Biol. Chem., March 3, 2006; 281(9): 6058 - 6069.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
G. E. Davis and D. R. Senger
Endothelial Extracellular Matrix: Biosynthesis, Remodeling, and Functions During Vascular Morphogenesis and Neovessel Stabilization
Circ. Res., November 25, 2005; 97(11): 1093 - 1107.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology.